Novel Treatment Options for <em>T790M</em>-Mutant Non-Small Cell Lung Cancer
Despite initial clinical benefit of erlotinib and geftinib, overall efficacy of these agents is limited by emergence of drug-resistance mutations, including the gatekeeper T790M mutation.